Last update 16 May 2025

QLS1304

Overview

Basic Info

Drug Type
Small molecule drug
Synonyms
QLS1304
Target
KAT6A x KAT6B
Action
inhibitors
Mechanism
KAT6A inhibitors(lysine acetyltransferase 6A inhibitors), KAT6B inhibitors(lysine acetyltransferase 6B inhibitors)
Therapeutic Areas
NeoplasmsSkin and Musculoskeletal Diseases
Active Indication
Advanced cancerAdvanced Malignant Solid NeoplasmER-positive/HER2-negative Breast Cancer
Inactive Indication-
Originator Organization
Qilu Pharmaceutical Co., Ltd.Qilu Pharmaceutical Co., Ltd.
Active Organization
Qilu Pharmaceutical GroupQilu Pharmaceutical GroupShanghai Qilu Pharmaceutical Research Center Co., Ltd.Qilu Pharmaceutical Co., Ltd.Qilu Pharmaceutical Co., Ltd.
Inactive Organization-
License Organization-
Drug Highest PhasePhase 1
First Approval Date-
RegulationFast Track (United States)
Login to view timeline

Related

1
Clinical Trials associated with QLS1304
NCT06823609
/ Not yet recruitingPhase 1
A Phase I Clinical Study to Evaluate Safety, Tolerability, PK Characteristic and Preliminary Efficacy of QLS-1304 in Patients With Advanced Malignant Tumors
100 Clinical Results associated with QLS1304
Login to view more data
100 Translational Medicine associated with QLS1304
Login to view more data
100 Patents (Medical) associated with QLS1304
Login to view more data
100 Deals associated with QLS1304
Login to view more data

R&D Status

10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Advanced cancerPhase 1-
Qilu Pharmaceutical Co., Ltd.Qilu Pharmaceutical Co., Ltd.
01 Mar 2025
Advanced Malignant Solid NeoplasmPhase 1
China
Qilu Pharmaceutical Co., Ltd.Qilu Pharmaceutical Co., Ltd.
14 Feb 2025
ER-positive/HER2-negative Breast CancerIND Approval
United States
Qilu Pharmaceutical GroupQilu Pharmaceutical Group
27 Apr 2025
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
AACR2025
Not Applicable
KAT6A amplification | H3K23Ac | ER expression ...
View more
-
tgxzqbefdy(mjnaflqwfs) = suppressed in KAT6A-high cells wgpxykzhjh (ynkgdjidfd )
View more
-
27 Apr 2025
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
login
or
view full example data
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
login
or
view full example data
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
login
or
view full example data
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
login
or
view full example data
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
login
or
view full example data
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
login
or
view full example data
Understand key drug designations in just a few clicks with Synapse.
AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free